Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
On Thursday, Piper Sandler reaffirmed its Overweight rating on Lexicon Pharmaceuticals (NASDAQ:LXRX) stock, maintaining a $10.00 price target. The affirmation follows Lexicon's announcement of an exclusive licensing agreement with VTRS for the drug sotagliflozin outside the United States and the European Union.
Lexicon Pharmaceuticals will receive a $25 million upfront payment as part of the deal. The company is also set to receive additional milestone payments and tiered royalties on net sales, ranging from low-double-digit to upper-teen percentages. This partnership is seen as a significant opportunity for Lexicon, as it retains ownership of sotagliflozin in the most valuable markets, namely the U.S. and Europe.
The agreement with VTRS is viewed by Piper Sandler as a reflection of Lexicon's strategic approach to partnerships and business development. The firm's analyst believes that the deal underscores the company's thoughtful strategy in these areas.
The analyst from Piper Sandler conveyed optimism regarding the potential of Lexicon's stock, citing the recent update to their financial model. The update includes an analysis of eight key reasons supporting the current opportunity to invest in Lexicon Pharmaceuticals. The partnership and the strategic retention of sotagliflozin rights in key markets are central to this positive outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.